A Kinetic Model Explains Why Shorter and Less Affine Enzyme-recruiting Oligonucleotides Can Be More Potent

Molecular Therapy Nucleic Acids

Volumn 3, Issue , 2014, Pages

  Pedersen, Lykke ^a   Hagedorn, Peter H ^a,b   Lindholm, Marie Wickström ^b   Lindow, Morten ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Santaris Pharma AS   (Denmark)

Author keywords

kinetic model; oligonucleotide affinity; potency

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; OLIGONUCLEOTIDE; RIBONUCLEASE H; RNA; SMALL INTERFERING RNA; MICRORNA;

ARTICLE; BINDING AFFINITY; CHEMICAL MODIFICATION; ENZYME DEGRADATION; ENZYME KINETICS; EXPERIMENT; HYBRIDIZATION; LAW; MASS ACTION; PRIORITY JOURNAL; RNA DEGRADATION; COMPLEX FORMATION; DOSE RESPONSE; HUMAN; HYDROGEN BOND; IN VITRO STUDY; KINETICS; PROTEIN SECONDARY STRUCTURE; REVERSE TRANSCRIPTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RNA HYBRIDIZATION; TURNOVER TIME;

EID: 84894522337     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2013.72     Document Type: Article

References (38)

1. Walder, RY and Walder, JA (1988). Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci USA 85: 5011-5015.
2. Stein, H and Hausen, P (1969). Enzyme from calf thymus degrading the RNA moiety of DNA-RNA Hybrids: effect on DNA-dependent RNA polymerase. Science 166: 393-395.
3. Zamecnik, PC and Stephenson, ML (1978). Inhibition of Rous sarcoma virus replication and cell transformation by a specifc oligodeoxynucleotide. Proc Natl Acad Sci USA 75: 280-284. (Pubitemid 8290783)
4. Bennett, CF and Swayze, EE (2010). RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 50: 259-293.
5. Obika, S, Nanbu, D, Hari, Y, Morio, K, In, Y, Ishida, T et al. (1997). Synthesis of 2-O, 4-C-methyleneuridine and-cytidine. Novel bicyclic nucleosides having a fxed C3,-endo sugar puckering. Tet Lett 38, 8735-8738. (Pubitemid 27504436)
6. Koshkin, AA, Singh, SK, Nielsen, P, Rajwanshi, VK, Kumar, R, Meldgaard, M et al. (1998). LNA (Locked Nucleic Acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron 54, 3607-3630. (Pubitemid 28108183)
7. Frieden, M, Christensen, SM, Mikkelsen, ND, Rosenbohm, C, Thrue, CA, Westergaard, M et al. (2003). Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA. Nucleic Acids Res 31: 6365-6372. (Pubitemid 37442364)
8. Straarup, EM, Fisker, N, Hedtjärn, M, Lindholm, M W, Rosenbohm, C, Aarup, V et al. (2010). Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res 38: 7100-7111.
9. Manoharan, M (1999). 2'-carbohydrate modifcations in antisense oligonucleotide therapy: importance of conformation, confguration and conjugation. Biochim Biophys Acta 1489: 117-130.
10. Hovingh, K, Besseling, J and Kastelein, J (2013). Effcacy and safety of mipomersen sodium (Kynamro). Expert Opin Drug Saf 12: 569-579.
11. Swayze, EE and Bhat, B (2007). The medicinal chemistry of oligonucleotides. In: Crooke, ST (ed.). Antisense Drug Technology. CRC: Boca Raton, FL.
12. Seth, P P, Siwkowski, A, Allerson, CR, Vasquez, G, Lee, S, Prakash, TP et al. (2009). Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J Med Chem 52: 10-13.
13. Stanton, R, Sciabola, S, Salatto, C, Weng, Y, Moshinsky, D, Little, J et al. (2012). Chemical modifcation study of antisense gapmers. Nucleic Acid Ther 22: 344-359.
14. Herschlag, D (1991). Implications of ribozyme kinetics for targeting the cleavage of specifc RNA molecules in vivo: more isn't always better. Proc Natl Acad Sci USA 88: 6921-6925. (Pubitemid 21915061)
15. Larsson, E, Sander, C and Marks, D (2010). mRNA turnover rate limits siRNA and microRNA effcacy. Mol Syst Biol 6: 433.
16. Roth, CM (2005). Molecular and cellular barriers limiting the effectiveness of antisense oligonucleotides. Biophys J 89: 2286-2295. (Pubitemid 41401020)
17. Brown, KS and Sethna, JP (2003). Statistical mechanical approaches to models with many poorly known parameters. Phys Rev E Stat Nonlin Soft Matter Phys 68(2 Pt 1): 021904.
18. Crooke, ST (2008). Antisense Drug Technologies: Principles, Strategies, and Applications. CRC Press: Boca Raton, FL.
19. Obad, S, dos Santos, CO, Petri, A, Heidenblad, M, Broom, O, Ruse, C et al. (2011). Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 43: 371-378.
20. Lima, W F, Monia, B P, Ecker, DJ and Freier, SM (1992). Implication of RNA structure on antisense oligonucleotide hybridization kinetics. Biochemistry 31: 12055-12061. (Pubitemid 23011348)
21. Patzel, V, zu Putlitz, J, Wieland, S, Blum, HE and Sczakiel, G (1997). Theoretical and experimental selection parameters for HBV-directed antisense RNA are related to increased RNA-RNA annealing. Biol Chem 378: 539-543. (Pubitemid 27296329)
22. Jo, JJ, Kim, MJ, Son, J T, Kim, J and Shin, JS (2009). Single-fuorophore monitoring of DNA hybridization for investigating the effect of secondary structure on the nucleation step. Biochem Biophys Res Commun 385: 88-93.
23. Rauzan, B, McMichael, E, Cave, R, Sevcik, LR, Ostrosky, K, Whitman, E et al. (2013). Kinetics and thermodynamics of DNA, RNA, and hybrid duplex formation. Biochemistry 52: 765-772.
24. Gillespie, DT (1977). Exact stochastic simulation of coupled chemical reactions. J Phys Chem 81: 2340-2361.
25. Stein, CA, Subasinghe, C, Shinozuka, K and Cohen, JS (1988). Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res 16: 3209-3221.
26. Lorenz, R, Bernhart, SH, Höner Zu Siederdissen, C, Tafer, H, Flamm, C, Stadler, PF et al. (2011). ViennaRNA Package 2.0. Algorithms Mol Biol 6: 26.
27. Arvey, A, Larsson, E, Sander, C, Leslie, CS and Marks, DS (2010). Target mRNA abundance dilutes microRNA and siRNA activity. Mol Syst Biol 6: 363.
28. Brown, PN, Byrne, GD and Hindmarsh, AC (1989). VODE, a variable-coeffcient ODE solver. SIAM J Sci Stat Comput 10, 1038-1051.
29. Mergny, JL and Lacroix, L (2003). Analysis of thermal melting curves. Oligonucleotides 13: 515-537. (Pubitemid 38296149)
30. Chaires, JB (2008). Calorimetry and thermodynamics in drug design. Annu Rev Biophys 37: 135-151.
31. Sugimoto, N, Nakano, S, Katoh, M, Matsumura, A, Nakamuta, H, Ohmichi, T et al. (1995). Thermodynamic parameters to predict stability of RNA/DNA hybrid duplexes. Biochemistry 34: 11211-11216.
32. McTigue, PM, Peterson, RJ and Kahn, JD (2004). Sequence-dependent thermodynamic parameters for locked nucleic acid (LNA)-DNA duplex formation. Biochemistry 43: 5388-5405. (Pubitemid 38620931)
33. Owczarzy, R, You, Y, Groth, CL and Tataurov, AV (2011). Stability and mismatch discrimination of locked nucleic acid-DNA duplexes. Biochemistry 50: 9352-9367.
34. SantaLucia, J Jr (1998). A unifed view of polymer, dumbbell, and oligonucleotide DNA nearest-neighbor thermodynamics. Proc Natl Acad Sci USA 95: 1460-1465.
35. Amirkhanov, N V, Pradeepkumar, PI and Chattopadhyaya, J (2002). Kinetic analysis of the RNA cleavage of the conformationally-constrained oxetane-modifed antisense-RNA hybrid duplex by RNase H. J Chem Soc Perkin Trans 2: 976-984 (Pubitemid 35188168)
36. Lodish, H (2008). Molecular Cell Biology (W. H. Freeman: Hampshire, UK).
37. Yang, E, van Nimwegen, E, Zavolan, M, Rajewsky, N, Schroeder, M, Magnasco, M et al. (2003). Decay rates of human mRNAs: correlation with functional characteristics and sequence attributes. Genome Res 13: 1863-1872. (Pubitemid 36987192)
38. Christensen, U, Jacobsen, N, Rajwanshi, VK, Wengel, J and Koch, T (2001). Stopped-fow kinetics of locked nucleic acid (LNA)-oligonucleotide duplex formation: studies of LNA-DNA and DNA-DNA interactions. Biochem J 354(Pt 3): 481-484. (Pubitemid 32269710)